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Adenovirusinfectioncancausevariousillnessesdependingontheinfectingserotype,suchasgastroenteritis,conjunctivitis,cystitis,
and rash illness, but the infection mechanism is still unknown. MicroRNAs (miRNA) have been reported to play essential roles
in cell proliferation, cell diﬀerentiation, and pathogenesis of human diseases including viral infections. We analyzed the miRNA
expressionproﬁlesfromadenovirustype3(AD3)infectedHumanlaryngealepithelial(Hep2)cellsusingaSOLiDdeepsequencing.
492 precursor miRNAs were identiﬁed in the AD3 infected Hep2 cells, and 540 precursor miRNAs were identiﬁed in the control. A
total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control.
The biogenesis of miRNAs has been analyzed, and some of the SOLiD results were conﬁrmed by Quantitative PCR analysis. The
present studies may provide a useful clue for the biological function research into AD3 infection.
1.Introduction
Adenovirus (AD) belongs to a family of nonenveloped
icosahedral viruses containing a double-stranded DNA
genome, Adenoviridae,a n dg e n u sMastadenovirus. There are
53 human AD serotypes divided into seven subgroups (A
to G) based on immunologic, biologic, and biochemical
characteristics [1]. Among these, viruses in groups B1,
C, and E cause respiratory infections, group B2 viruses
infect the kidney and urinary tract; group F viruses cause
gastroenteritis; and several group D serotypes are associated
with epidemic keratoconjunctivitis [1]. Most people recover
from AD infections by themselves, but people with immun-
odeﬁciency and small children are at higher risk of fatal
adenovirusinfection. Studies showed thatADcanevadehost
immuneresponses,suchasinhibitionofinterferonfunctions
by RNA and E1A, and inhibition of intrinsic cellular
apoptosis in infected cells [2]. The interaction between the
virus and its host is still not clear. Recently, several studies
evaluated human adenoviruses which play an important
role in the study of tumorigenesis, including oncogenic
transformation of cells, immune evasion, angiogenesis, and
metastasis [3, 4]. There are no antiviral drugs to treat
adenoviral infections, so treatment is largely directed at
the symptoms. The discovery of the AD yielded further
evidence that viruses can sometimes interfere with each
other during the growth and replication within a host
animal. Other researchers found that this interference can
be mediated by interferon produced by the host animal.
So interferon has become prominent in the treatment of a
variety of cancers and infectious diseases, such as hepatitis
C[ 5]. Recently, several studies demonstrated that RNA
interference (RNAi) can also be used for treatment with viral
infection in vitro, such as hepatitis B virus, coxsackievirus
B3, and Coxsackievirus A16 [6–8]. These ﬁndings indicate
that those speciﬁc siRNAs targeted viruses are not as eﬀective
as expected.
RNAi can also be triggered by microRNAs (miRNAs),
which are short ∼22 nucleotide RNA sequences that bind
complementary sequences in the 3  U T Ro fm u l t i p l et a r g e t2 Journal of Biomedicine and Biotechnology
mRNAs, playing an important role in the development,
proliferation, diﬀerentiation and apoptosis of organisms.
Growing evidences have indicated a strong association
between microRNAs and various viral infections. For exam-
ple, miR-125b, mirR-150, miR-382, and miR-223 have
been reported to contribute to the maintenance of human
immunodeﬁciency virus-1 (HIV-1) latency in resting CD4+
T cells [9]. Epstein-Barr virus and Kaposi sarcoma herpes
viruses(KSHVs)havebeenreportedtoencodemiRNAs[10],
but the functions of most of them are not known. miRNAs
have been reported to be used as a tool for gene speciﬁc
therapeutics against viral infections [11]. The potential use
ofmiRNAsasnovelnoninvasivebiomarkersfordiagnosishas
been suggested in other studies [12–14].
In this study, we used a strategy of initial screening
by Applied Biosystems’ next generation sequencing system
which is Sequencing by Oligonucleotide Ligation and Detec-
tion (SOLiD) and validation by quantitative RT-PCR (qRT-
PCR), to analyze the diﬀerent miRNA expression proﬁling in
AD3 infected Hep2 cells.
2.MaterialsandMethods
2.1. Cell Culture and Virus Infection. Human laryngeal
epithelial (Hep2) cells were cultivated in complete RPMI
medium 1640 (Invitrogen) supplemented with 10% fetal calf
serum (FCS) at 37
◦Ci na na t m o s p h e r eo f5 %C O 2. When
t h eH e p 2c e l l sw e r eg r o w ni n2 5 - c m 2 ﬂasks reached to 70%
conﬂuence, they were infected with AD3 at a multiplicity of
infection (m.o.i.) of 0.4 under 50% tissue culture infectious
doses (TCID50), and maintained after infection at 37
◦Ci n
RPMI 1640 medium with 2% FCS.
2.2. RNA Isolation. Hep2 cells were infected with AD3 as
described above. At 6 hours, 24 hours, 48 hours, and 72
hours post infection (p.i.), RNA samples were prepared
from AD3 infected Hep2 cells and controlled Hep2 cells
using a mirVana miRNA Isolation Kit (Ambion): 102–107
culturedcellswerewashedin1%PBSforthreetimes,washed
cells were mixed with 600μl Lysis/Binding Solution and
1/10 volume of miRNA Homogenate Additive thoroughly
by vortexing and incubated on ice for 10 minutes An
equalvolumeofacid/phenol/chloroform(Ambion)wasthen
added to the each aliquot. The solution was centrifuged for
5 minutes at 10,000g at room temperature. For miRNA
isolation, the extraction was mixed thoroughly with 1/3
volume of 100% ethanol and passed through a column
(Ambion). The ﬂow-through was contained the small RNAs.
The ﬁltrate was then mixed thoroughly with 2/3 volume
100% ethanol and passed through the second column
(Ambion). The column was washed following the protocol,
a n dm i R N A sw e r ee l u t e di n1 0 0μlo fe l u t i o nb u ﬀer (95
◦C).
FortotalRNAisolation,theextractionwasmixedthoroughly
with 1.25 volume of 100% ethanol and passed through a
column (Ambion). The column was washed following the
protocol and total RNA were eluted in 100μlo fe l u t i o n
buﬀer (95
◦C). A total of 1μl of the eluate was quantiﬁed by
Nanodrop.
2.3. SOLiD Sequencing and Sequence Analysis. MiRNA sam-
ples (100ng) isolated from AD3 infected Hep2 cells and
control Hep2 cells were processed into sequencing libraries
using the Small RNA Expression Kit (Applied Biosystems).
Brieﬂy, RNA was ligated overnight with the adapters from
the kit, reverse transcribed, RNAse H-treated, and PCR-
ampliﬁed before size selection on Agarose gels to contain
16–61nt of inserted sequences. Libraries were ampliﬁed
onto beads using emulsion PCR, deposited on slides, and
sequenced using the SOLiD v 2 sequencing system (Applied
Biosystems) [15] at the State Key Lab of Bioelectronics
Laboratory, Southeast University of China. Finally, SOLiD
data was ﬁrst analyzed by SOLiD System Small RNA Analysis
Pipeline Tool (RNA2MAP). Firstly, the parameters set for
alignments were the maximum length (18nt) and the
tolerance of 3 mismatches when generating initial seeds
locations. In the extension step, less than 6 mismatches were
allowed in full length mapping. The miRBase sequences
(Sanger) of human being was download from miRBase
(http://www.mirbase.org/). Acceptable sequences were com-
pared to the miRBase database (release 14.0). To increase
signal above noise, we conservatively selected only those
alignments corresponding to beads sampled a minimum of
10 times in any of the libraries.
2.4. Quantitative RT-PCR (qRT-PCR). To conﬁrm the
expression of miRNAs by deep sequencing approach, stem-
loop quantitative RT-PCR (qRT-PCR) was performed.
Brieﬂy, cDNA was synthesized from total RNA by using
AMV reverse transcriptase (TaKaRa). The 20μL reactions
were incubated for 15 minutes at 16
◦C, 30 minutes at 42
◦C,
and 5 minutes at 85
◦C, and then held at 4◦C. Subsequently,
the 20μL PCR reactions included 1μlR T - P C Rp r o d u ct ,1 0μl
Premix Ex Taq (TaKaRa), and 1 μl SYBR green (Invitrogen).
The reactions were incubated in a 96-well optical plate
at 95
◦C for 10 minutes, followed by 40 cycles of 95
◦C
for 15 seconds, and 60
◦C for 1 minute. Q-PCR assay was
performed in triplicate using an ABI 7500 machine (Applied
Biosystems). The expression levels of candidate miRNAs
were measured in terms of threshold cycle value (CT)a n d
normalized to Human small nuclear RNA U6. The ratio of
two groups of miRNAs was calculated by using the equation
2−ΔΔCT [16], in which ΔCT1(infected cells) = CT1 − CTU6,
ΔCT2(control cells) = CT2 − CTU6 and ΔΔCT = ΔCT1 −
ΔCT2.
2.5. Statistical Analysis. We ﬁrstly used the Z-test to deter-
mine the statistical signiﬁcance of the diﬀerences between
the two libraries. This approach is to look at the number of
copies of a specic miRNA per cell as a fraction or proportion
of the total number of miRNA molecules in that cell. The
same proportion (p) of specic tags should be present in the
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So the Z-value for a speciﬁc miRNA could be calculated as
following:
Z-value =











The proportion p0, the expected proportion when the
null hypothesis is true, is calculated as p0 = (ntest +
ncontrol)/(Ntest + Ncontrol). The Z statistic is approximately
normally distributed and can be compared with critical Z
value for the two-sided signiﬁcance level α [17].
AZ-testwasusedtodealwiththerawdatabyconsidering
both the copies and fold change of miRNAs. Candidate
miRNAs should be full three criteria: (1) mean fold change
> 2, (2) having at least 10 copies by SOLiD sequencing, and
(3) Z score > 1.96 or < −1.96 for P<. 05.
3. Results
3.1. Replication of AD3 in Hep2 Cells. Cytopathic eﬀect
(CPE) was ﬁrst observed at 24 hours post infection and
progressed to moderate and severe CPE at 72 hours and
96 hours, respectively. miRNA extracted from cells after 72
hours of infection was used for SOLiD deep sequencing.
3.2. SOLiD Sequencing of miRNAs from Hep2 Cells Infected
by AD3 and Control Hep2 Cells. To search for the miRNAs
expression in AD3 infected Hep2 cells and the control,
we prepared these two miRNA samples for sequencing by
the SOLiD system. 358,297 eﬀective reads were obtained in
AD3 infected cells and 479,414 eﬀective reads in control
cells. After ﬁltrating reads contaminated by rRNAetc (rRNA,
tRNA, snRNA, and snoRNA), repeat fractions, and degraded
fractions, the remaining eﬀective reads were mapped to
the human precursor libraries. 37,800 and 78,143 reads
were obtained from infected and control cells, respectively.
In these reads, the most abundant size class was 22nt in
both of AD3 infected Hep2 cells and the control. The
percentage was 29.3% and 34.6% respectively. Following was
23nt (27.7% in AD3 infected Hep2 cells and 26.3% in the
control) (Figure 1). Compared to the miRBase (14.0), 492
precursor, miRNA out of 734 known precursor miRNAs
were identiﬁed among the AD3 infected Hep2 cells, and 540
precursor miRNAs were identiﬁed among the control Hep2
cells. All of the known miRNAs have been characterized in
the Sanger miRBase sequence database. Figure 2 showed the
distribution of genomic loci in the chromosome. All of the
human chromosome were located in the precursor miRNAs.
Chromosomes 19 and X contain more precursor miRNAs
(12%, and 11%, resp.). 314 miRNAs (51%) were located in
introns of protein-coding genes, 231 miRNAs (38%) were
located in intergenic regions, while only 43 miRNAs (7%)
were located in exons of noncoding RNAs or UTR of protein
coding genes. Interestedly, 23 miRNAs (4%) were located in
either an exon or an intron depending on alternative splicing
of the host transcript (Table 1).
3.3. Expression Proﬁles of miRNAs in AD3 Infected Cells. To
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Figure 2: Genomic loci of the sequenced miRNAs (Chr: chromo-
some).
Table 1: Transcript loci of sequenced miRNAs.
Loci Number of miRNAs Percentage (%)
intron 314 51
intergenic 231 38
Exon and Utr 42 7
Exon, intron (mixed) 23 4
between AD3 infected Hep2 cells and the control, both the
Z-test and fold-change analysis were made based on the
sequencing results. There are 80 precursor miRNAs to meet
the three criteria described above, and could be selected as
candidates. Among these candidates, 44 precursor miRNAs
were shown upregulated expression in AD3 infected cells
(Table 2). Z-test value was from 1.99 to 49.33. 19 out of 444 Journal of Biomedicine and Biotechnology
Table 2: Upexpressed miRNAs in infected cells compared with noninfected cells.




hsa-miR-1975 1937 548 49.33 7.47
hsa-miR-1302-2 788 228 31.13 7.31
hsa-miR-191 868 566 23.16 3.24
hsa-miR-17 1238 1105 21.65 2.37
hsa-miR-92a-2 1166 1084 20.17 2.27
hsa-miR-1979 444 201 20.02 4.67
hsa-miR-92a-1 1184 1146 19.48 2.18
hsa-miR-1302-3 197 58 15.45 7.18
hsa-miR-1302-8 191 54 15.38 7.48
hsa-miR-1302-6 191 57 15.16 7.09
hsa-miR-1302-7 191 57 15.16 7.09
hsa-miR-1302-1 180 59 14.32 6.45
hsa-miR-1302-5 165 50 14.03 6.98
hsa-miR-1302-4 161 50 13.76 6.81
hsa-miR-7-3 111 18 13.13 13.04
hsa-miR-7-1 150 50 13.00 6.34
hsa-miR-7-2 109 21 12.64 10.97
hsa-miR-1974 262 188 11.88 2.95
hsa-miR-1246 186 121 10.70 3.25
hsa-miR-378 220 199 8.95 2.34
hsa-miR-18a 185 153 8.92 2.56
hsa-miR-619 79 41 7.92 4.07
hsa-miR-25 178 172 7.52 2.19
hsa-miR-421 57 38 5.82 3.17
hsa-miR-1273 54 37 5.57 3.09
hsa-miR-18b 62 51 5.18 2.57
hsa-miR-345 50 37 5.07 2.86
hsa-miR-342 83 84 4.87 2.09
hsa-miR-744 28 19 4.03 3.12
hsa-miR-505 22 13 3.90 3.58
hsa-miR-1247 17 10 3.43 3.59
hsa-miR-942 12 6 3.14 4.23
hsa-miR-635 11 5 3.14 4.65
hsa-miR-627 12 7 2.90 3.62
hsa-miR-150 10 5 2.87 4.23
hsa-miR-566 10 5 2.87 4.23
hsa-miR-324 20 18 2.71 2.35
hsa-miR-146b 10 6 2.60 3.52
hsa-miR-454 10 6 2.60 3.52
hsa-miR-1972 14 12 2.37 2.47
hsa-miR-320c-2 14 13 2.20 2.28
hsa-miR-589 16 16 2.17 2.11
upregulated precursor miRNAs showed higher values (over
10). Among this, miR-1975 and miR-1302-2 have the highest
Z values with 49.33 and 31.13, respectively. Table 2 showed
the ratio of miRNAs expression level of AD3 infected cells
versus control cells. Among this, miR-1975 and miR-1302-2
have the higher ratio (7.47-fold and 7.31-fold). 36 precursor
miRNAs were shown downregulated expression in AD3
infected cells (Table 3). Among this there are 11 miRNAs
that have the higher Z values (over 10). Table 3 showed
the ratio of AD3 infected cells/control cells (expression levelJournal of Biomedicine and Biotechnology 5
Table 3: Downexpressed miRNAs in infected cells compared with noninfected cells.




hsa-miR-1184 3 21 −2.06 0.30
hsa-miR-1180 10 43 −2.06 0.49
hsa-miR-219-1 8 38 −2.14 0.45
hsa-miR-519a-1 6 33 −2.24 0.38
hsa-miR-433 6 35 −2.40 0.36
hsa-miR-650 6 35 −2.40 0.36
hsa-miR-148b 12 55 −2.49 0.46
hsa-miR-148a 13 60 −2.62 0.46
hsa-miR-196b 4 31 −2.62 0.27
hsa-miR-1259 6 46 −3.18 0.28
hsa-miR-362 30 128 −3.53 0.50
hsa-miR-181b-1 7 60 −3.80 0.25
hsa-miR-374b 8 65 −3.87 0.26
hsa-miR-655 26 126 −3.96 0.44
hsa-miR-33a 16 95 −3.99 0.36
hsa-miR-101-1 44 191 −4.40 0.49
hsa-miR-101-2 44 192 −4.43 0.48
hsa-miR-452 29 158 −4.87 0.39
hsa-miR-181b-2 8 91 −5.12 0.19
hsa-miR-26b 31 172 −5.14 0.38
hsa-let-7e 33 199 −5.84 0.35
hsa-miR-1274b 15 168 −6.93 0.19
hsa-miR-27b 139 677 −9.25 0.43
hsa-miR-34a 206 904 −9.70 0.48
hsa-miR-582 82 531 −9.95 0.33
hsa-miR-338 113 905 −14.40 0.26
hsa-miR-27a 248 1382 −14.68 0.38
hsa-miR-125b-1 399 2082 −17.23 0.41
hsa-miR-125b-2 443 2220 −17.25 0.42
hsa-miR-30b 219 1572 −18.12 0.29
hsa-miR-30c-2 233 1812 −20.19 0.27
hsa-miR-30c-1 232 1811 −20.22 0.27
hsa-miR-210 207 1738 −20.40 0.25
hsa-miR-19b-1 538 2952 −21.36 0.39
hsa-miR-19b-2 536 2946 −21.36 0.38
hsa-miR-30a 260 2083 −21.95 0.26
for precursor miRNAs). Among this miR-181b-2 and miR-
1274bshowed lowestchangeinAD3infectedcells(0.19fold)
compared with control cells.
3.4. Q-PCR Detection for miRNAs Proﬁles in AD3 Infected
Cells. To conﬁrm the diﬀerential expression of miRNAs
in AD3 infected Hep2 cells, we performed some miRNAs
tests with stem-loop Q-PCR assays in total RNA isolated
from AD3 infected Hep2 cells and the control, respectively.
The expression levels of candidate miRNAs were measured
in terms of threshold cycle value (CT) and normalized to
Human small nuclear RNA U6. The ratio of miRNAs in two
groups was calculated by using the equation 2−ΔΔCT.T h e
results showed that there was general consistency between
Q-PCR assay and SOLiD sequencing analysis. The seven
upregulated miRNAs in SOLiD results showed increased
ratios measured in Q-PCR assays (Figure 3). For example,
miR-1974, miR-1975, and miR-7 showed increasing values
of 2.51, 4.87 and 2.44 respectively measured in Q-PCR assay,
and increasing values of 2.95, 7.47 and 6.34 were obtained















































































































































































































Figure 3: Quantitation of miRNA expression levels in the AD3
infectedHep2cellsandcontrols.Yvaluesaretheratiooftwogroups
of miRNAs calculated by using the equation 2−ΔΔCT. The black
column is for upregulated miRNAs, and the gray for downregulated
miRNAs.
miRNAs in SOLiD results showed decrease ratios measured
in Q-PCR assays (Figure 3). For example, the results showed
decreased expression levels in miR-27b, miR-125b, and miR-
27a in AD3 infected Hep2 cells with fold change of 0.74,
0.75, and 0.77 respectively (Figure 3). While in SOLiD
sequencing analysis, these miRNAs have shown decreased
expression with fold change 0.43, 0.41 and 0.38, respectively
(Table 3). To further understand the miRNAs expression in
A D 3i n f e c t e dH e p 2c e l l sa t6h o u r s ,2 4h o u r s ,4 8h o u r s ,a n d
72 hours post infection, we performed Q-PCR experiments
on miRNAs chosen from Figure 3. The ratio of miRNAs in
AD3 infected cells versus controls was calculated by using
the equation 2−ΔΔCT. Surprisingly, all of the miRNAs shown
in Table 4 exhibited increased expression in AD3 infected
cells at 6 hours post infection. However, at 48 hours p.i. and
72 hours p.i., miR-27b, miR-125b, and miR-181b showed
downregulated expression in AD3 infected cells comparing
controls (Table 4). At 48 hours p.i. and 72 hours p.i., miR-
1974 showed increased expression in AD3 infected cells
with fold change 1.36 and 1.26 respectively. However, at 24
hours p.i., miR-1974 showed decreased expression in AD3
infected cells. Table 4 showed that the miR-17 expression
was upregulated at 6, 24, and 72 hours p.i. in AD3 infected
cells. But at 48 hours p.i., miR-17 showed downregulated
expression in AD3 infected cells.
4. Discussion
As second-generation sequencing platforms have matured,
all three major high-throughput sequencing systems—
Illumina’s Genome Analyzer (Solexa), Life Technologies’
ABI SOLiD, and Roche’s 454 GS FLX have been used to
study miRNA expression proﬁles associated with disease
such as cancer, viral and metabolic diseases. Compared with
the microarray technology, deep sequencing can generate
Table 4: The ratio of ADV-3 infected cells/control cells at diﬀerent
time course after the infection.








hsa-miR-27b 2.77 1.25 0.32 0.66
hsa-miR-125b 2.39 0.47 0.56 0.84
hsa-miR-181b 1.73 0.62 0.52 0.62
hsa-miR-1974 1.62 0.4 1.36 1.26
hsa-miR-17 2.81 1.6 0.44 1.33
p.i. refers to post infection. The ratio of miRNAs in two groups was
calculated by using the equation 2−ΔΔCT.
millions of small RNA sequence reads from a given sample,
giving possible to discover the novel miRNAs or study the
function of virus encoded miRNAs by using bioinformatics
and molecular biology tools. miRNAs have recently been
recognized as major regulators of gene expression in various
viral infections. Virus-encoded miRNAs seem to evolve
rapidly and regulate both the viral life cycle and the
interaction between viruses and their hosts. In the present
study, we have screened out some miRNA candidates that
haveobviousdiﬀerentialexpressionfromAD3infectedHep2
cells by SOLiD deep sequencing system.
This study identiﬁed 492 precursor miRNAs in the AD3
infected cells and more precursor miRNAs in control cells
by mapping the human miRBase database. Out of these
almost 38% were located in intergenic regions, which usually
contain their own miRNA gene promoter and regulatory
units [18]. However, as much as 51% miRNAs were located
in introns, and only 7% were located in exons of noncoding
RNAs or UTR of protein coding genes. These usually
show a concurrent transcription and regulation expression
proﬁle originating from a common promoter with their
host genes [19–21]. Some pre-miRNAs existing in drosphila
and ce l e g a n t shave been reported to be spliced from the
introns in which they reside without having to undergo
the microprocessor machinery. These miRNAs are called
mirtrons [22, 23]. Since our study identiﬁed 51% miRNAs
were located in introns, we think more mirtons could be
discovered through bioinformatics and molecular biology
tools.
The interaction between the AD and its host is still
unknown. One of the mechanisms is that the virus must
interfere with the host cell antiviral defense mechanisms to
maximize escape and spread of the progeny virus during a
virus infection [24]. Previous studies determine the changes
in the host cell gene expression proﬁles upon infection
with AD using DNA microarray technique [24, 25]. For
example,manytranscriptionsfactorE2F-dependenthostcell
genes showed diﬀerent expression during AD infection. 45%
of the upregulated genes and 25% of the downregulated
genes contained potential E2F binding sites [24]. It is
showen that E2F-dependent host cell genes are subjected
to a selective regulation. However, the mechanism of AD
infection after transcription is still unknown. miRNA can
regulate gene expression through translational repression or
mRNA cleavage. Previous research has reported that theJournal of Biomedicine and Biotechnology 7
expression of E2F1 is negatively regulated by two c-myc-
regulated miRNAs, miR-17-5p, and miR-20a [26]. In our
study, upregulated miR-17 may target with transcription
factor E2F1 [26], playing important role in cell diﬀeren-
tiation, proliferation, and apoptosis. Out of these, miR-17
has been reported to be overexpression in B-cell lymphoma
samples [27]. The high miR-17 cluster miRNAs suppress
cell death [27]. This suggests that during a virus infection,
cellular apoptosis must delay long enough and the virus
needs to establish optimal conditions for replication to
ensure eﬃcient production of progeny virus. Our study may
provide a useful clue for the biological function research into
AD3 infected host cells. Further investigation needs to clarify
the roles of identiﬁed miRNAs in the pathogenesis of AD3
infected host cells.
5. Conclusion
SOLiD sequencing provides a useful method for identiﬁ-
cation of the miRNAs proﬁles in AD3 infected Hep2 cells.
492 precursor miRNAs were identiﬁed in the AD3 infected
Hep2 cells, and 540 precursor miRNAs were identiﬁed in the
control. A total of 44 miRNAs demonstrated high expression
and36miRNAsshowedlowerexpressionintheAD3infected
cells than the control. Further studies are required to identify
the miRNA target genes and the functions of the miRNAs in
the complex molecular network regulation during the virus
infection host cells using bioinformatics tools.
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